NeuroSense Therapeutics Ltd. — Form 6-K
Reporting context: Furnished October 13, 2026, for the month of October 2026. The filing reports that the company issued a press release titled “NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones.” The press release itself is not included in the supplied filing text.
Financial and operating information
The supplied text contains no revenue, profit, cash flow, margin, debt, liquidity, or other financial figures. It provides no comparative-period results.
Outlook, risks, and unusual items
The press release title refers to a Nasdaq hearing and upcoming PrimeC regulatory and funding milestones, but the filing text does not provide the hearing date, milestone details, funding terms, management commentary, or related risks or contingencies.
The filing states that specified paragraphs of the press release are incorporated by reference into the company’s listed Form S-8 and Form F-3 registration statements, to the extent not superseded by later filings or furnished reports.
Important facts for investors to verify
- Review Exhibit 99.1 for the Nasdaq hearing date, status, and potential consequences.
- Verify the timing and nature of PrimeC’s regulatory milestones and any associated contingencies.
- Review the press release for funding plans, terms, and any impact on liquidity or dilution.